Plain-English definitions for every term you'll encounter on your GLP-1 journey — backed by peer-reviewed research and clinical guidelines.
Category
The molecules, the manufacturing, and how compounded GLP-1s differ from brand-name versions.
The active pharmaceutical ingredient in Ozempic, Wegovy, and Rybelsus — a GLP-1 receptor agonist administered weekly by injection or daily as an oral tablet. It is the same molecule whether branded or compounded.
Why it matters: Understanding that semaglutide is the molecule — not the brand — helps clarify why compounded versions contain the same therapeutic agent as brand-name products.
Source: FDA Ozempic LabelThe active pharmaceutical ingredient in Mounjaro and Zepbound — a dual GIP and GLP-1 receptor agonist administered weekly by injection. The dual mechanism produces greater average weight loss than semaglutide in clinical trials.
Why it matters: Tirzepatide is currently the most potent approved weight loss medication available.
Source: Jastreboff et al., NEJM SURMOUNT-1 Trial, 2022A medication prepared by a licensed compounding pharmacy for a specific patient using pharmaceutical-grade ingredients. Compounded semaglutide contains the same active molecule as Ozempic or Wegovy but is not manufactured by Novo Nordisk and is not approved as a finished drug product.
Why it matters: Compounding allows access to the same therapeutic molecule at a fraction of brand-name prices when prepared by a licensed pharmacy.
Source: FDA — Compounding Laws and PoliciesThe actual drug molecule in a medication — the part that produces the therapeutic effect. In compounded semaglutide, the API is semaglutide itself, the same molecule found in Ozempic and Wegovy.
Why it matters: When evaluating compounded GLP-1 quality, the source and purity of the API is what counts — not the brand name on the label.
Source: FDA — Human Drug CompoundingA short chain of amino acids. Semaglutide and tirzepatide are both peptide-based medications, which is why they must be injected — peptides are broken down by stomach acid and cannot be absorbed effectively as oral medications at standard doses.
Why it matters: This explains why GLP-1 medications are weekly injections rather than daily pills, though oral semaglutide at higher doses is now available.
Source: Drucker, Cell Metabolism, 2018Pharmacy Compounding Accreditation Board certification — a voluntary quality credential demonstrating that a compounding pharmacy meets rigorous safety and quality standards verified by independent audit.
Why it matters: PCAB accreditation is the clearest independent signal of compounding pharmacy quality — always ask if your GLP-1 provider's pharmacy partner is PCAB-accredited.
Source: ACHC PCAB Accreditation ProgramSterile water containing a small amount of benzyl alcohol, used to reconstitute compounded GLP-1 medications in vial form. The benzyl alcohol prevents bacterial growth and extends shelf life.
Why it matters: Using the wrong diluent can degrade your medication — always use bacteriostatic water unless your provider specifies otherwise.
Source: FDA — Human Drug Compounding (Sterile Preparation)Prescribing a medication for a purpose, dose, or population not listed in the approved label. Ozempic is frequently prescribed off-label for weight loss even though Wegovy is the approved weight loss version of the same molecule.
Why it matters: Off-label prescribing is legal and common — it does not mean the use is unsafe or unsupported by clinical evidence.
Source: FDA — Understanding Unapproved Use of Approved DrugsCategory
How GLP-1 dosing works — from your first injection to long-term maintenance.
The structured process of gradually increasing GLP-1 medication from a low starting dose to a therapeutic maintenance dose, typically over 12–20 weeks. This allows the GI tract to adapt and minimizes nausea and vomiting.
Why it matters: Skipping escalation steps dramatically increases side effect severity — the schedule exists for good reason.
Source: Wilding et al., NEJM STEP 1 Trial, 2021The final therapeutic dose of GLP-1 medication reached after completing the escalation schedule. For semaglutide this is typically 2.4mg weekly. For tirzepatide it ranges from 10–15mg weekly depending on response and tolerance.
Why it matters: Clinical trial weight loss results are measured at maintenance dose — results during escalation are typically lower.
Source: FDA Wegovy LabelA patient who loses less than 5% of body weight after 12–16 weeks at maintenance dose. Approximately 10–15% of GLP-1 patients are non-responders. Non-response is usually addressed by switching medications.
Why it matters: If you are not losing weight after 3–4 months at full dose, your provider should evaluate whether a medication switch is appropriate rather than continuing an ineffective treatment.
Source: Rubino et al., JAMA, 2022Category
How GLP-1 medications actually work inside your body.
A hormone naturally produced in your gut after eating that signals fullness, stimulates insulin release, and slows digestion. GLP-1 medications mimic and amplify this natural hormone.
Why it matters: This is the foundational mechanism behind all semaglutide and tirzepatide medications.
Source: Holst, Physiological Reviews, 2007A gut hormone that works alongside GLP-1 to regulate insulin secretion and fat metabolism. Tirzepatide activates both GIP and GLP-1 receptors simultaneously.
Why it matters: The addition of GIP agonism is the key pharmacological reason tirzepatide outperforms semaglutide in weight loss comparisons.
Source: Finan et al., Science Translational Medicine, 2013A medication that activates two hormone receptors simultaneously. Tirzepatide is a dual GIP and GLP-1 receptor agonist, which is why it produces greater average weight loss than semaglutide in head-to-head comparisons.
Why it matters: The dual mechanism is the pharmacological reason SURMOUNT-1 trial results exceeded what was seen in semaglutide trials.
Source: Jastreboff et al., NEJM SURMOUNT-1 Trial, 2022A class of gut hormones including GLP-1 and GIP that stimulate insulin secretion in response to food intake. GLP-1 medications are sometimes called incretin mimetics.
Why it matters: The incretin system is why GLP-1 medications lower blood sugar without causing dangerous hypoglycemia in non-diabetic patients.
Source: Drucker & Nauck, The Lancet, 2006The rate at which your stomach moves food into the small intestine. GLP-1 medications slow this process, which extends fullness signals and reduces post-meal blood sugar spikes.
Why it matters: Slowed gastric emptying is both why GLP-1 medications are so effective and why high-fat meals cause discomfort on medication.
Source: Nauck et al., Diabetologia, 1997A condition where cells don't respond normally to insulin, requiring the pancreas to produce more to maintain normal blood sugar. It is the underlying mechanism of prediabetes and type 2 diabetes.
Why it matters: GLP-1 medications directly improve insulin sensitivity — one reason they are effective for both weight loss and diabetes management.
Source: Kahn et al., Journal of Clinical Investigation, 2006The constant mental preoccupation with food — thinking about what to eat next, craving specific foods, feeling driven to eat even when not physically hungry. One of the most commonly reported benefits of GLP-1 medications is dramatically reduced food noise.
Why it matters: Many patients describe food noise reduction as the most life-changing effect of GLP-1 treatment — more impactful day-to-day than the weight loss itself.
Source: Blundell et al., Diabetes, Obesity and Metabolism, 2017The weight range your body actively defends through hormonal and metabolic mechanisms. GLP-1 medications are thought to lower the defended set point by reducing the hormonal drive to regain weight.
Why it matters: Set point theory explains why diet and exercise alone often fail long-term — and why pharmacological intervention may be necessary for sustained results.
Source: Leibel et al., New England Journal of Medicine, 1995Your body's metabolic defense mechanism against weight loss — it reduces calorie burn beyond what is expected from mass loss alone, often by 200–400 calories per day. GLP-1 medications partially offset this through their effects on energy regulation.
Why it matters: It's the main reason weight loss slows after the first few months even when you're doing everything right.
Source: Rosenbaum & Leibel, Journal of Clinical Investigation, 2010Category
The numbers your provider tracks before and during treatment.
A number calculated from height and weight used as a screening tool for weight classification. BMI 18.5–24.9 is normal, 25–29.9 is overweight, 30 or above is obese. GLP-1 medications are typically prescribed for BMI 30+ or BMI 27+ with a weight-related condition.
Why it matters: BMI is the primary eligibility criterion for GLP-1 prescription — though it has known limitations as a measure of metabolic health.
Source: FDA Wegovy Prescribing InformationA blood test measuring average blood sugar over the past 2–3 months, expressed as a percentage. Normal is below 5.7%. Pre-diabetes is 5.7–6.4%. Type 2 diabetes is 6.5% and above. GLP-1 medications reduce A1C by 1.5–2.3%.
Why it matters: A1C reduction is one reason GLP-1 medications are prescribed for both diabetes management and weight loss.
Source: American Diabetes Association Standards of Care 2024Category
What's happening to your body during weight loss — and how to protect what matters.
The weight of everything in your body that isn't fat — muscle, bone, organs, and water. Preserving lean mass during weight loss is critical for long-term metabolic health and physical function.
Why it matters: Approximately 25% of weight lost on GLP-1 medications is lean mass — protein intake and resistance training are essential to minimize this.
Source: Wilding et al., NEJM STEP 1 Trial, 2021Fat stored around internal organs in the abdominal cavity. More metabolically dangerous than subcutaneous fat, visceral fat is strongly associated with insulin resistance, cardiovascular disease, and systemic inflammation.
Why it matters: GLP-1 medications preferentially reduce visceral fat — patients often notice waist circumference changes before the scale reflects significant total weight loss.
Source: Després & Lemieux, Nature, 2006Age-related muscle loss that accelerates after age 50. GLP-1 medications can compound natural muscle loss if protein intake and resistance training are not prioritized during treatment.
Why it matters: Women over 50 on GLP-1 therapy face the highest sarcopenia risk and should prioritize 1.2–1.6g of protein per kilogram of ideal body weight daily from day one.
Source: Cruz-Jentoft et al., Age and Ageing, 2019Temporary hair shedding triggered by physiological stress including rapid weight loss. It typically begins 2–4 months after significant weight loss starts and resolves within 6–12 months. It is not a direct drug effect.
Why it matters: Hair thinning on GLP-1 medications is almost always temporary and related to weight loss rate — not a permanent side effect of the medication itself.
Source: Asghar & Bhatt, StatPearls, 2023Category
The landmark studies that shaped how GLP-1 medications are prescribed today.
A series of clinical trials studying semaglutide for weight management. STEP 1, the landmark trial published in NEJM in 2021, showed 14.9% average body weight reduction over 68 weeks in adults with obesity.
Why it matters: STEP trial data is the clinical foundation for semaglutide's approval for weight management and is what providers reference when discussing expected outcomes.
Source: Wilding et al., NEJM STEP 1 Trial, 2021Clinical trials studying tirzepatide for weight management. SURMOUNT-1 showed up to 22.5% average body weight reduction at the 15mg dose — results previously associated only with bariatric surgery.
Why it matters: SURMOUNT results established tirzepatide as the most effective approved weight loss medication to date.
Source: Jastreboff et al., NEJM SURMOUNT-1 Trial, 2022A major cardiovascular outcomes trial published in the New England Journal of Medicine in 2023 showing that semaglutide 2.4mg reduced major cardiovascular events by 20% in patients with obesity and pre-existing cardiovascular disease.
Why it matters: This trial transformed GLP-1 medications from weight loss drugs into recognized cardiovascular protection agents.
Source: Lincoff et al., NEJM SELECT Trial, 2023Category
The federal rules, pharmacy classifications, and insurance frameworks that shape GLP-1 access.
A list maintained by the US Food and Drug Administration identifying medications that are in short supply. When a drug appears on the shortage list, licensed compounding pharmacies may legally prepare copies of that drug under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
Why it matters: The FDA Drug Shortage List was the legal foundation that enabled compounded semaglutide and tirzepatide to be widely prescribed between 2022 and 2025.
Source: FDA Drug ShortagesA traditional compounding pharmacy that prepares medications for individual patients based on a valid prescription from a licensed prescriber. 503A pharmacies are regulated primarily by state boards of pharmacy.
Why it matters: Most telehealth GLP-1 providers — including Ozari Health — work with 503A compounding pharmacies. 503A status means medications are prepared individually under a valid prescription, not manufactured in bulk.
Source: FDA — Compounding Under FDCA Sections 503A and 503BAn FDA-registered compounding facility that can produce large quantities of compounded medications without individual patient prescriptions. Following the FDA's removal of semaglutide from the shortage list in February 2025, 503B facilities were prohibited from compounding copies of semaglutide.
Why it matters: The distinction between 503A and 503B is critical in 2026. 503B facilities can no longer legally compound semaglutide. Only licensed 503A pharmacies with documented individual patient need may do so.
Source: FDA — Outsourcing Facilities Under Section 503BA third-party compliance verification issued by LegitScript, an independent healthcare compliance company. LegitScript-certified operators have been verified to operate legally, employ licensed healthcare professionals, require valid prescriptions, and comply with applicable laws.
Why it matters: LegitScript certification is one of the clearest trust signals for online GLP-1 providers. It is also required to run paid advertising on Google and Meta for prescription medications.
Source: LegitScript Healthcare Merchant Certification ProgramA requirement from a health insurance plan that a prescriber must obtain approval before a specific medication is covered. GLP-1 medications for weight loss face prior authorization requirements at most major commercial insurance plans.
Why it matters: Prior authorization is the primary reason insured patients turn to cash-pay telehealth for GLP-1 access. The approval process can take weeks and is frequently denied.
Source: American Medical Association — Prior Authorization ResearchCategory
How online GLP-1 care is delivered — and the clinical frameworks behind it.
A medical specialty focused on the prevention, evaluation, and treatment of overweight and obesity as a chronic disease. Board-certified obesity medicine physicians complete additional training beyond their base specialty.
Why it matters: Providers with obesity medicine training are more likely to understand GLP-1 pharmacology, appropriate dose escalation, side effect management, and long-term treatment planning.
Source: American Board of Obesity MedicineA federal law that establishes national standards for protecting sensitive patient health information. All telehealth providers handling patient medical records are required to comply with HIPAA Privacy and Security Rules.
Why it matters: When sharing your medical history with an online GLP-1 provider, HIPAA compliance ensures your data cannot be sold to third parties for marketing purposes.
Source: US Department of Health & Human Services — HIPAA for IndividualsA condition that exists simultaneously with another primary condition. For GLP-1 eligibility, relevant comorbidities include type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and cardiovascular disease. Having one or more of these with a BMI of 27 or above qualifies a patient for GLP-1 prescriptions.
Why it matters: Patients with a BMI below 30 who have weight-related health conditions are eligible for GLP-1 medications — many patients are unaware that the 27+ BMI threshold applies.
Source: FDA Wegovy Prescribing Information — Indications and UsageThis glossary is for informational purposes only and does not constitute medical advice. Source links are provided for reference and do not imply endorsement. Always consult a licensed healthcare provider before starting any medication.
Tools
Quick reference tools to help you plan your GLP-1 journey. Estimates only — always discuss with your provider.
Total Daily Energy Expenditure estimates how many calories your body burns each day at your current activity level.
These tools are calculated approximations and not a substitute for medical advice. Accuracy may vary for those with high muscle mass, those who are pregnant or lactating, children, older adults, or anyone with specific medical conditions. Discuss your results with a licensed provider.
Open a dedicated calculator page to bookmark or share a direct link.